CMS Open Payments · Program Year 2024
Avita Medical Americas, Llc
Avita Medical Americas, Llc reported $1,602,377.84 across General Payments, Research, and Ownership to 2,776 physicians and teaching hospitals across 2,860 transactions.
- $1.6M Above-median payer
- All-tracks total
- 2,860 Top quartile volume
- Transactions
- 2,776 Top quartile reach
- Recipients
- −$118.8K
- General Payments vs PY2023
Avita Medical Americas, Llc reported $1,602,377.84 across all CMS Open Payments tracks (General + Research + Ownership) to 2,776 physicians and teaching hospitals in Program Year 2024 - ranking #505 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $544,951.27, averaging $577.23 per recipient.
How Avita Medical Americas, Llc's $1.6M all-tracks total breaks down
Avita Medical Americas, Llc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
38/100
Total payments
F
25/100
Transaction volume
F
31/100
Physician reach
F
31/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer avita-medical-americas-llc Avita Medical Americas, Llc
$1.6M · #505/1,925 · 0.0% industry · PY2024
- TOT $1.6M
- RANK #505
- SHARE 0.0%
- TXN 2,860
- RCP 2,776
- CAT 5
- GEN $545.0K
- ΔGEN −$118.8K
- TOP1 7.2%
- PY 2024
Volume peers
Nearest volume peer: Grifols Shared Services North America, Inc. ($1.6M)
Avita Medical Americas, Llc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Avita Medical Americas, Llc's CMS-reported General Payments decreased by $118.8K (−17.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: AVITA MEDICAL AMERICAS, LLCPY2023: AVITA MEDICAL AMERICAS, LLCPY2024: Avita Medical Americas, Llc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $663,712.16
- PY2024
- $544,951.27
What the Data Shows for Avita Medical Americas, Llc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Avita Medical Americas, Llc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $170.4K, accounting for 31.3% of this company's General Payments and 90 transactions.
General Payment Breakdown by Type
"Consulting Fee" leads Avita Medical Americas, Llc's 5-category general-payment breakdown at $170.4K, 31.3% of the reported total.
Avita Medical Americas, Llc reports 5 general-payment categories - the top three are Consulting Fee (31.3%), Food and Beverage (27.5%), and Honoraria (23.4%). The remaining 2 categories make up 17.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Avita Medical Americas, Llc divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $170.4K | 90 | 31.3% |
| Food and Beverage | $150.1K | 2,362 | 27.5% |
| Honoraria | $127.5K | 62 | 23.4% |
| Travel and Lodging | $95.4K | 261 | 17.5% |
| Compensation for Services Other Than Consulting | $1.5K | 1 | 0.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $158,586.45 (29.1%) of $544,951.27 in this company's General Payments records across 1,562 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Avita Medical Americas, Llc
The five named recipients with the highest reported General Payments from this company
- 1
Ian Valerio
$39,303.03 across 69 reported transactions
- 2
Derek Bell
$32,016.60 across 70 reported transactions
- 3
Carmen Flores
$29,985.83 across 65 reported transactions
- 4
Jeffrey Carter
$29,057.09 across 30 reported transactions
- 5
Rajiv Sood
$28,223.90 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Avita Medical Americas, Llc ranks #505 of 1,925 by total payments (top 26% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,501 of 1,838 by HHI (bottom 18% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Aveo Pharmaceuticals, Inc. : $486.7K total payments, HHI 267
- Escala Medical Inc. : $6.0K total payments, HHI 266
- Elucent Medical : $251.3K total payments, HHI 265
- AltaThera Pharmaceuticals LLC : $230.3K total payments, HHI 265
- Team 1, Llc : $78.3K total payments, HHI 263
- ConvaTec Inc. : $8.5M total payments, HHI 261
- Avita Medical Americas, Llc (this company) : $545.0K total payments, HHI 257
- Core Surgical Group : $20.0K total payments, HHI 256
- Curonix LLC : $754.8K total payments, HHI 254
- Argon Medical Devices, Inc. : $147.3K total payments, HHI 254
- Averitas Pharma Inc. : $1.5M total payments, HHI 253
- Ambu A/S : $181.1K total payments, HHI 252
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Avita Medical Americas, Llc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Avita Medical Americas, Llc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Avita Medical Americas, Llc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Rigel Pharmaceuticals, Inc.
Ethicon US, LLC
restor3d, inc.
Zavation Medical Products, LLC
Datascope Corp.
Put this to use
Avita Medical Americas, Llc ranks #505 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Avita Medical Americas, Llc sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Avita Medical Americas, Llc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.